RP1208
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Psoriasis, Depression, Obesity
Key Facts
About Reviva Pharmaceuticals
Reviva Pharmaceuticals is a clinical-stage biotech focused on addressing high-burden diseases with significant unmet medical needs, primarily in neuropsychiatry. Its core strategy is built around its internally discovered lead candidate, brilaroxazine, which demonstrated positive topline results in a pivotal Phase 3 schizophrenia trial (RECOVER) and is being developed for a broad spectrum of CNS indications. The company is navigating the late-stage regulatory pathway, having received FDA feedback requiring a second Phase 3 trial prior to an NDA submission, while concurrently advancing a second pipeline candidate, RP1208, for pulmonary and metabolic conditions. Reviva aims to establish brilaroxazine as a potential best-in-class, broad-spectrum neuropsychiatric therapy.
View full company profile